Anti-HER2/Neu Antibody Therapy Inhibits HER2 <sup>+</sup> Breast Cancer by Blocking Myeloid-Derived Suppressor Cell Activity
Tumor suppression by anti-neu antibodies is associated with a reduction in MDSCs via the inhibition of key MDSC-related factors. MDSCs may be therapeutic targets for increasing Herceptin efficacy in patients with breast cancer.
Authors
- Jae‐Hyeog Choi (ORCID: https://orcid.org/0000-0003-4130-7132)
- Tae-Hoon No (ORCID: https://orcid.org/0000-0002-0112-0042)
- Ji Young Lee
- Ki Hyang Kim (ORCID: https://orcid.org/0000-0002-4760-0228)
- SaeGwang Park (ORCID: https://orcid.org/0000-0002-2163-2010)
- Xingguo Quan
- Y.-J. Lee (ORCID: https://orcid.org/0000-0002-1744-4041)
- Myoung Joo Kang (ORCID: https://orcid.org/0000-0002-4334-4028)
- So Young Jung (ORCID: https://orcid.org/0000-0003-0155-5473)
- Jin Lee (ORCID: https://orcid.org/0000-0003-2124-4963)
- Jin‐Hee Park (ORCID: https://orcid.org/0000-0002-0069-7819)
- Won Sik Lee (ORCID: https://orcid.org/0000-0001-9502-2429)
- Chul Hoi Jeong (ORCID: https://orcid.org/0000-0002-3033-9908)
- Il Hwan Kim
- Byeonghwa Bak
- Sung Sook Lee
- Sung-Nam Lim
Institutions
- Inje University (KR)
- Inje University Haeundae Paik Hospital (KR)
- Inje University Busan Paik Hospital (KR)
- Busan Medical Center (KR)
- Daegu-Gyeongbuk Medical Innovation Foundation (KR)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1159/000549018
- Primary Topic
- Immune cells in cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.00